share_log

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K：重大事件
美股sec公告 ·  05/14 16:49
Moomoo AI 已提取核心訊息
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company based in Lexington, Massachusetts, reported significant amendments to its financial structure. The company disclosed the conversion of $15.0 million of its outstanding debt into equity with CRG Servicing LLC, resulting in the issuance of 3,280,618 shares of Common Stock and 17,146.48 shares of Series A Convertible Preferred Stock. This follows a similar transaction on July 3, 2023, where $10.0 million of debt was converted into 483,457 shares of Common Stock and 93,297.26 shares of Series B Convertible Preferred Stock. The recent amendments involved the removal of beneficial ownership limitations, allowing for the conversion of all outstanding Series A and Series B Preferred Stock into 1,824,800 shares of Common Stock. Consequently, CRG now owns approximately 69% of T2 Biosystems' outstanding shares. The company's common stock is traded on the Nasdaq Global Market under the symbol TTOO.
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company based in Lexington, Massachusetts, reported significant amendments to its financial structure. The company disclosed the conversion of $15.0 million of its outstanding debt into equity with CRG Servicing LLC, resulting in the issuance of 3,280,618 shares of Common Stock and 17,146.48 shares of Series A Convertible Preferred Stock. This follows a similar transaction on July 3, 2023, where $10.0 million of debt was converted into 483,457 shares of Common Stock and 93,297.26 shares of Series B Convertible Preferred Stock. The recent amendments involved the removal of beneficial ownership limitations, allowing for the conversion of all outstanding Series A and Series B Preferred Stock into 1,824,800 shares of Common Stock. Consequently, CRG now owns approximately 69% of T2 Biosystems' outstanding shares. The company's common stock is traded on the Nasdaq Global Market under the symbol TTOO.
2024年5月9日，總部位於馬薩諸塞州列剋星敦的醫療診斷公司T2 Biosystems, Inc. 報告了其財務結構的重大修改。該公司披露了將其在CRG Servicing LLC的1,500萬美元未償債務轉換爲股權的情況，從而發行了3,280,618股普通股和17,146.48股A系列可轉換優先股。在此之前，2023年7月3日進行了一次類似的交易，其中1,000萬美元的債務被轉換爲483,457股普通股和93,297.26股B系列可轉換優先股。最近的修正案涉及取消實益所有權限制，允許將所有已發行的A系列和B系列優先股轉換爲1,824,800股普通股。因此，CRG現在擁有T2 Biosystems約69％的已發行股份。該公司的普通股在納斯達克全球市場上市，股票代碼爲TTOO。
2024年5月9日，總部位於馬薩諸塞州列剋星敦的醫療診斷公司T2 Biosystems, Inc. 報告了其財務結構的重大修改。該公司披露了將其在CRG Servicing LLC的1,500萬美元未償債務轉換爲股權的情況，從而發行了3,280,618股普通股和17,146.48股A系列可轉換優先股。在此之前，2023年7月3日進行了一次類似的交易，其中1,000萬美元的債務被轉換爲483,457股普通股和93,297.26股B系列可轉換優先股。最近的修正案涉及取消實益所有權限制，允許將所有已發行的A系列和B系列優先股轉換爲1,824,800股普通股。因此，CRG現在擁有T2 Biosystems約69％的已發行股份。該公司的普通股在納斯達克全球市場上市，股票代碼爲TTOO。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息